Search

Your search keyword '"Jørgensen, Erik"' showing total 29 results
Start Over Author "Jørgensen, Erik" Publisher wiley
29 results on '"Jørgensen, Erik"'

1. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure

Author

Qayyum, Abbas Ali, primary, Mouridsen, Mette, additional, Nilsson, Brian, additional, Gustafsson, Ida, additional, Schou, Morten, additional, Nielsen, Olav Wendelboe, additional, Hove, Jens Dahlgaard, additional, Mathiasen, Anders Bruun, additional, Jørgensen, Erik, additional, Helqvist, Steffen, additional, Joshi, Francis Richard, additional, Johansen, Ellen Mønsted, additional, Follin, Bjarke, additional, Juhl, Morten, additional, Højgaard, Lisbeth Drozd, additional, Haack‐Sørensen, Mandana, additional, Ekblond, Annette, additional, and Kastrup, Jens, additional

Published
2023
Full Text
View/download PDF

6. The benefit of complete revascularization after primary PCI for STEMI is attenuated by increasing age: Results from the DANAMI‐3‐PRIMULTI randomized study

Author

Joshi, Francis R., primary, Lønborg, Jacob, additional, Sadjadieh, Golnaz, additional, Helqvist, Steffen, additional, Holmvang, Lene, additional, Sørensen, Rikke, additional, Jørgensen, Erik, additional, Pedersen, Frants, additional, Tilsted, Hans Henrik, additional, Høfsten, Dan, additional, Køber, Lars, additional, Kelbæk, Henning, additional, and Engstrøm, Thomas, additional

Published
2020
Full Text
View/download PDF

8. Invasive angiography and revascularization in patients with stable angina following prior coronary artery bypass grafting: Results from the East Denmark heart registry

Author

Joshi, Francis R., primary, Biasco, Luigi, additional, Pedersen, Frants, additional, Holmvang, Lene, additional, Helqvist, Steffen, additional, Tilsted, Hans-Henrik, additional, Abildgaard, Ulrik, additional, Kelbaek, Henning, additional, Lassen, Jens F., additional, Jørgensen, Erik, additional, De Backer, Ole, additional, and Engstrøm, Thomas, additional

Published
2016
Full Text
View/download PDF

17. Fate and effects of esfenvalerate in agricultural ponds

Author

Samsøe-Petersen, Lise, primary, Gustavson, Kim, additional, Madsen, Torben, additional, Mogensen, Betty Bügel, additional, Lassen, Pia, additional, Skjernov, Kamilla, additional, Christoffersen, Kirsten, additional, and Jørgensen, Erik, additional

Published
2001
Full Text
View/download PDF

21. Malignant Histiocytosis

Author

ØSter‐Jørgensen, Erik, primary, Rønne, Mogens, additional, Jensen, Niels Kristoffer, additional, and Grunnet, Niels, additional

Published
1983
Full Text
View/download PDF

28. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial.

Author

Qayyum AA, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, Nadrowski P, Paitazoglou C, Vrtovec B, Bergmann MW, Chamuleau SAJ, Wojakowski W, Gyöngyösi M, Kraaijeveld A, Hansen KS, Vrangbaek K, Jørgensen E, Helqvist S, Joshi FR, Johansen EM, Follin B, Juhl M, Højgaard LD, Mathiasen AB, Ekblond A, Haack-Sørensen M, and Kastrup J

Subjects
Humans, Chronic Disease, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Double-Blind Method, Heart Failure, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cells
Abstract

Aims: The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC&#95;ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF)., Methods and Results: The study was a European multicentre, double-blind, placebo-controlled phase II trial using allogeneic CSCC&#95;ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II-III, left ventricular ejection fraction (LVEF) <45%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels >300 pg/ml. CSCC&#95;ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6-month follow-up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac-related adverse events during a 3-year follow-up period. There were no significant differences between groups during follow-up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end-diastolic volume (-2.0 ± 6.0 ml, p = 0.736) and LVEF (-1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-min walk test, NT-proBNP, C-reactive protein or quality of life the first year in any groups., Conclusion: The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC&#95;ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2023
Full Text
View/download PDF

29. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial.

Author

Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Kofoed KF, Haack-Sørensen M, Ekblond A, and Kastrup J

Subjects
Adult, Aged, Aged, 80 and over, Bone Marrow, Follow-Up Studies, Humans, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardial Ischemia complications, Myocardial Ischemia surgery, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Heart Failure therapy, Mesenchymal Stem Cells
Abstract

Aims: The study assessed 4-year outcomes of intramyocardial injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs) in patients with ischaemic heart failure., Methods and Results: The MSC-HF trial was a randomized, double-blind, placebo-controlled trial. Patients were randomized 2:1 to intramyocardial injections of MSCs or placebo. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography. Sixty patients aged 30-80 years with ischaemic heart failure, New York Heart Association class II-III, left ventricular ejection fraction (LVEF) <45% and no further treatment options were randomized. Patients were followed clinically for 12 months and in addition 4-year data of hospitalizations and survival were retrieved. After 12 months, LVESV was significantly reduced in the MSC group and not in the placebo group, with difference between groups of 17.0 ± 16.2 mL (95% confidence interval 8.3-25.7, P = 0.0002). There were also significant improvements in LVEF of 6.2% (P < 0.0001), stroke volume of 16.1 mL (P < 0.0001) and myocardial mass (P = 0.009) between groups. A significant dose-response effect was also observed. Moreover, a significant reduction in the amount of scar tissue and quality of life score in the MSC group but not in the placebo group was observed. After 4 years, there were significantly fewer hospitalizations for angina in the MSC group and otherwise no differences in hospitalizations or survival. No side effects were identified., Conclusions: Intramyocardial injections of autologous bone marrow-derived MSCs improved myocardial function and myocardial mass in patients with ischaemic heart failure., (© 2019 European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results